| Name | Title | Contact Details |
|---|
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.
Dompé: un impegno costante nella ricerca scientifica per lo sviluppo di farmaci innovativi per migliorare lo stato di salute dell’uomo
Watson Laboratories is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.